Article and Video CATEGORIES
This week, the US FDA made a public announcement to alert the public that it had received reports of several patient deaths from the technique of radiofrequency ablation (RFA) to lung tumors. This is an investigational technique that I described in a prior post, after several members asked about RFA. I made the point that while it was an option to consider, it was still early in development and was not an option that I thought would be a leading option except in very unusual circumstances. You heard it here first...
There have been some individuals and centers that have been liberal in their marketing of this technique, including for lung tumors. The FDA warning highlights the danger of marketing hype getting ahead of the evidence supporting the safety and clinical benefit of a new technique or drug, which really need to be subjected to thorough clinical testing. These trials are well regulated and closely monitored, and their results will move the field forward. Accordingly, the FDA warning mentions that RFA should preferably be conducted on lung tumors in the setting of a clinical trial.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…